Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing
BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Professor Umberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II of Naples, Italy and the Scientific Secretary of the International Society of Liquid Biopsy, championed the new applications to support his research on lung and other cancers.
"When I learned SOPHiA GENETICS was offering applications from MSK on the SOPHiA DDM™ platform, I was really interested in the evaluation of the performance of this test, in particular because I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research," said Professor Malapelle.
"Bringing best-in-class technology to global organizations is crucial to help advance better health care for all. We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care," said Ross Muken, President, SOPHiA GENETICS.
Of the thirty-seven institutions adopting MSK solutions, thirty-four have signed on to adopt MSK-ACCESS® powered with SOPHiA DDM™, just ten months after the Liquid Biopsy application's launch. The decentralized deployment of MSK-ACCESS® has enabled hospitals and labs across the globe to launch world-renowned Liquid Biopsy testing from within the walls of their own institution, providing patients with a less-invasive option for genomic testing. In many cases, this decentralized testing also results in lower costs and faster turnaround times, while also enabling institutions to retain control of their patients' data for research or other purposes.
Internationally recognized organizations adopting the application include: Heidelberg University Hospital in Germany; Biopticka Laboratory in the Czech Republic; Hospital del Mar and Hospital La Fe in Spain; University Hospital of Nice and Marseille Regional Hospital Center in France; and Jewish General Hospital in Canada.
The complementary solid tumor application, MSK-IMPACT® powered with SOPHiA DDM™, has also attracted significant interest from leading organizations across the globe, including: the Jiménez Díaz Foundation University Hospital in Spain; the Cyprus Institute of Neurology and Genetics in Cyprus; and Sofiva Genomics in Taiwan.
Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS partnered in 2023 with a vision to use the sophisticated technology of the SOPHiA DDM™ Platform to bring MSK's state-of-the-art cancer testing capabilities to precision medicine institutions worldwide. The two leaders launched the Liquid Biopsy test MSK-ACCESS® powered with SOPHiA DDM™ in April 2024. In October 2024, SOPHiA GENETICS announced a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™, aiming to increase the availability of this innovative Liquid Biopsy solution worldwide. In November 2024, SOPHiA GENETICS announced the launch of the complementary Solid Tumor test, MSK-IMPACT® powered with SOPHiA DDM™. These collaborations have the potential to transform cancer research as they enable healthcare providers to draw from a continuously evolving base of real-world data and gain insights from diverse populations while using best-in-class technology.
Join us on Tuesday, February 25, 2025, at 11:00 a.m. (11:00) EDT / 5:00 p.m. (17:00) CET for the Precision Oncology Showcase, a virtual webinar which will spotlight the transformative potential of decentralized, AI-driven technologies for the advancement of cancer care.
About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
Forward-Looking StatementsThis press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-healthcare-institutions-adopt-msk-access-for-liquid-biopsy-testing-302383208.html
SOURCE SOPHiA GENETICS
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2025/24/c7219.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
44 minutes ago
- Wall Street Journal
Dow, S&P 500, Nasdaq All Positive on the Year Once Again
All three major U.S. stock indexes closed in positive year-to-date territory simultaneously for the first time since Feb. 21. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average all rose by 1%, or more, during Friday's trading. Stocks have been volatile through weeks of tariff news, but have recovered losses from recent months. This year, the S&P 500 is up 2%, the Nasdaq is up 1.1% and the Dow is up 0.5%, according to Dow Jones Market Data.
Yahoo
an hour ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Shopify Stock Popped Today
A Wells Fargo analyst raised their price target on Shopify's stock today. They called the company their "signature pick" and believe it could be a lesser-known beneficiary of the AI revolution. Home to its Shopify Magic and Sidekick solutions, Shopify looks more poised to thrive amid AI's rise, rather than be disrupted by it. 10 stocks we like better than Shopify › Shares of North America's leading commerce enabler, Shopify (NASDAQ: SHOP), were 6% higher as of 3:30 p.m. ET Friday, according to data provided by S&P Global Market Intelligence. This rise stems from an analyst at Wells Fargo raising their price target on the stock from $107 to $125, naming Shopify a "signature pick." Although Nvidia, Palantir, OpenAI, and others capture most of the artificial intelligence (AI) fanfare, the analyst believes Shopify could prove to be a thematic AI story -- and I'd agree. In April this year, a leaked memo from Chief Executive Officer Tobi Lütke went viral. In it, he stated, "Before asking for more headcount and resources, teams must demonstrate why they cannot get what they want done using AI." Although this focuses on incorporating AI into Shopify's operations, the quote highlights that AI will be at the heart of what the company does going forward, whether internally or through its products. In 2023, the company launched Shopify Magic, a toolbox of AI-powered solutions (think AI-generated product descriptions or email campaigns, automated chat help, or image editing). Then, it launched Sidekick -- an AI-driven commerce assistant -- in 2024 to help with areas such as inventory optimization, pricing strategies, and gathering business insights. Just last quarter, Shopify launched This tool enables merchants to source products more effectively, allowing them to navigate the complex tariff environment in real time. Adding over 600 new product features for its merchants in the last two years alone, Shopify appears likely to remain an AI innovator rather than a disruptee, in my opinion. Though Shopify stock isn't cheap at 83 times cash from operations, its growth potential remains massive, holding only a 2% market share in its core geographies. Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Josh Kohn-Lindquist has positions in Nvidia and Shopify. The Motley Fool has positions in and recommends Nvidia, Palantir Technologies, and Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Popped Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
